International Journal of Health & Allied Sciences

REVIEW ARTICLE
Year
: 2020  |  Volume : 9  |  Issue : 4  |  Page : 322--328

Nanoparticle-based dry Powder Inhaler-Based Approach for Corona Virus Disease-2019 Treatment: An Update


Kumar Ajay1, Ashish K Garg2, Sweta Garg3, Shevtank Bhatt4, Neeraj Mishra4 
1 Department of Pharmacology, Government Pharmacy Institute, Agam Kuan, Patna, Bihar, India
2 Department of P.G. Studies and Research in Chemistry and Pharmacy, Rani Durgavati University, Jabalpur, India
3 Department of Pharmaceutical Chemistry, Kailash Narayan Patel College of Pharmacy, Bhopal, Madhya Pradesh, India
4 Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, Madhya Pradesh, India

Correspondence Address:
Dr. Neeraj Mishra
Amity Institute of Pharmacy, Amity University Madhya Pradesh, Maharajpura, Gwalior - 474 005, Madhya Pradesh
India

Corona virus disease-2019 (COVID 19) is a respiratory disorder caused by bunches of serious respiratory disorders (i.e., coughing, fever, and breathing problems) like severe acute respiratory syndrome (SARS), and the 79% homology as well as gene sequences are basically similar to SARS-CoV, thus the name of COVID-19 also be distinguish as SARS-CoV-2 on January 7th. Nanoparticles may also improve drug pulmonary efficacy by enhancing residence time, as a consequence the efficient mucus complexation between mucin and nanoparticles caused increment the rate of permeation and tissue uptake and displayed sustainable release property. Advances in device technology have led to the development of more efficient delivery systems capable of delivering larger doses and finer particles into the lung. As more efficient pulmonary delivery devices and sophisticated formulations become available, physicians, and health professionals will have a choice of a wide variety of device and formulation combinations that will target-specific cells or regions of the lung, avoid the lung's clearance mechanisms and be retained within the lung for longer periods. Dry powder inhalers (DPIs) exhibit many unique advantages that have contributed to the incredible growth in the number of DPI pharmaceutical products. To improve the performance, there are a relatively large number of DPI devices available for different inhalable powder formulations. The present review different type of nanoaparticles and DPIs used for the treatment of COVID 19 infections.


How to cite this article:
Ajay K, Garg AK, Garg S, Bhatt S, Mishra N. Nanoparticle-based dry Powder Inhaler-Based Approach for Corona Virus Disease-2019 Treatment: An Update.Int J Health Allied Sci 2020;9:322-328


How to cite this URL:
Ajay K, Garg AK, Garg S, Bhatt S, Mishra N. Nanoparticle-based dry Powder Inhaler-Based Approach for Corona Virus Disease-2019 Treatment: An Update. Int J Health Allied Sci [serial online] 2020 [cited 2020 Nov 27 ];9:322-328
Available from: https://www.ijhas.in/article.asp?issn=2278-344X;year=2020;volume=9;issue=4;spage=322;epage=328;aulast=Ajay;type=0